- Home
- ENVX vs CLDX Comparison
ENVX vs CLDX Comparison
Compare ENVX & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVX
- CLDX
- Stock Information
- Founded
- ENVX 2006
- CLDX 1983
- Country
- ENVX United States
- CLDX United States
- Employees
- ENVX N/A
- CLDX N/A
- Industry
- ENVX Industrial Machinery/Components
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ENVX Miscellaneous
- CLDX Health Care
- Exchange
- ENVX Nasdaq
- CLDX Nasdaq
- Market Cap
- ENVX 2.1B
- CLDX 1.7B
- IPO Year
- ENVX N/A
- CLDX 2008
- Fundamental
- Price
- ENVX $10.72
- CLDX $22.46
- Analyst Decision
- ENVX Strong Buy
- CLDX Buy
- Analyst Count
- ENVX 11
- CLDX 8
- Target Price
- ENVX $20.64
- CLDX $61.86
- AVG Volume (30 Days)
- ENVX 6.2M
- CLDX 739.2K
- Earning Date
- ENVX 02-19-2025
- CLDX 03-04-2025
- Dividend Yield
- ENVX N/A
- CLDX N/A
- EPS Growth
- ENVX N/A
- CLDX N/A
- EPS
- ENVX N/A
- CLDX N/A
- Revenue
- ENVX $23,074,000.00
- CLDX $9,976,000.00
- Revenue This Year
- ENVX $195.38
- CLDX N/A
- Revenue Next Year
- ENVX $72.33
- CLDX N/A
- P/E Ratio
- ENVX N/A
- CLDX N/A
- Revenue Growth
- ENVX 201.86
- CLDX 128.55
- 52 Week Low
- ENVX $5.70
- CLDX $20.91
- 52 Week High
- ENVX $18.68
- CLDX $53.18
- Technical
- Relative Strength Index (RSI)
- ENVX 44.47
- CLDX 42.55
- Support Level
- ENVX $10.06
- CLDX $22.38
- Resistance Level
- ENVX $11.80
- CLDX $23.69
- Average True Range (ATR)
- ENVX 0.89
- CLDX 1.07
- MACD
- ENVX -0.10
- CLDX 0.03
- Stochastic Oscillator
- ENVX 26.03
- CLDX 44.67
About ENVX Enovix Corporation
Enovix Corp is engaged in the business of advanced silicon-anode lithium-ion battery development and production. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable the widespread utilization of renewable energy.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.